Stephen L. Hoffman M.D., D.T.M.H., CAPT, MC, USN (RET)
Dr. Hoffman has over 25 years of experience building and managing large, successful research and development programs. From 1987-2001 he was Director of the Malaria Program at the Naval Medical Research Center where he built a focused professional team of over 100 individuals in the United States and overseas working on all aspects of malaria research, but especially vaccine development and genomics. Dr. Hoffman and his team were leaders in the effort to sequence the P. falciparum genome and conducted the first studies in the world that showed that DNA vaccines elicited killer T cell responses in humans. In early 2001 Dr. Hoffman retired from the Navy and joined Celera Genomics as Senior Vice President of Biologics to create a program to utilize genomics and proteomics to produce new biopharmaceuticals. He established this program, organized the effort that successfully sequenced the genome of the mosquito responsible for most transmission of malaria in Africa, Anopheles gambiae, and left Celera in August 2002 to found Sanaria. He holds several professorships, and chairs or serves on multiple advisory boards. He is a past president of the American Society of Tropical Medicine and Hygiene, has edited two books on malaria vaccine development, been the author of more than 380 scientific publications, and has numerous patents. He is the most highly cited author in the world for scientific papers on malaria published between 1995 and 2005. He received his B.A. from the University of Pennsylvania, M.D. from Cornell University Medical College, Diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine, and did residency training at the University of California, San Diego. He is board certified in Family Practice. In 2004 he was elected to membership in the Institute of Medicine of the National Academies.
B. Kim Lee Sim, PhD
Dr. Sim, has been associated with Sanaria since its inception, and is a member of the board of Sanaria. She is also President and Chief Scientific Officer of Protein Potential LLC (www.proteinpotential.com), a vaccine development company, which she founded in 2003. Dr. Sim did her undergraduate (B.Sc., Honors, First Class) and graduate studies (M.Sc., Ph.D.) at the University of Malaya, Kuala Lumpur, Malaysia. After a post doctoral fellowship in molecular biology at Harvard School of Public Health, she was a research scientist at the Walter Reed Army Institute of Research and an adjunct faculty at the Uniformed Services University of Health Sciences, a research assistant professor at Johns Hopkins School of Public Health, and an Expert at the National Institute of Allergy and Infectious Diseases, NIH. In 1993 Dr. Sim left the NIH to join a start up company, EntreMed Inc, as Research Director of Molecular Biology, and in 1999 she was appointed Vice President Pre-Clinical Research and Development. At EntreMed, Dr. Sim established and managed the development program for anti-angiogenic proteins for the therapy of cancer, and developed the process that led to the cGMP manufacture of tens of kilograms of recombinant Angiostatin and Endostatin, two anti-angiogenic proteins that entered Phase II clinical trials. Dr. Sim has published more than 85 scientific papers, and has 7 issued and more than 15 pending patents.
Judith L. Harris, JD
Ms. Harris is a Partner in the Regulatory Litigation Group, Reed Smith LLC. She is former Managing Partner of the D.C. office, and has practiced with the firm since 1974, with the exception of two periods of government service. Most recently, Ms. Harris served during the Clinton Administration as Director of the Office of Legislative and Intergovernmental Affairs at the Federal Communications Commission. In that capacity, she was the Commission's primary interface with Capitol Hill, with the Administration, and with all Executive Branch and independent government agencies. Before entering the government, Ms. Harris' practice primarily focused on antitrust and trade regulation counseling, civil and criminal litigation, and administrative law, handling regulatory and APA matters before a wide array of federal agencies and in the courts, with a particular emphasis on the healthcare and telecommunications industries. Since returning to private practice, Ms. Harris has continued to work in the healthcare and telecom sectors, concentrating on matters before the FCC, the Justice Department, the Federal Trade Commission, in the courts and on Capitol Hill. In addition to her recent government position, Ms. Harris served as a senior trial attorney with the Antitrust Division of the Department of Justice, both in Washington, D.C. and in San Francisco, and was a law clerk to the Honorable James A. Belson, now of the D.C. Court of Appeals. Ms. Harris is a 1973 graduate of the Yale Law School and a 1970 graduate (Phi Beta Kappa, with highest distinction) of the University of Michigan. She resides in Washington, DC with her husband, Norman Ornstein. They have two grown sons.
James E. Schrager, MBA, CPA, JD and PhD
James E. Schrager is a Clinical Professor of Entrepreneurship and Strategy at the University of Chicago Graduate School of Business. In addition, he has an active strategy consulting firm in South Bend, IN, and is founding editor of the Journal of Private Equity, published by Institutional Investors, New York, NY. His educational background includes MBA, CPA, JD and PhD degrees. He previously completed deals and turned around businesses for Chicago's Pritzker family interests, where the largest business he turned around was $500 million in revenue. He also led the first private USA company to go public in Japan in 1989. His articles have appeared on the op-ed pages of the Chicago Tribune, the Wall Street Journal, and other publications, he has appeared on the NBC Nightly News, the PBS Business Report and other television shows, and has been widely quoted in many publications.
Adel A. F. Mahmoud, M.D., Ph.D
Adel A. F. Mahmoud, M.D., Ph.D is at The Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University. He has recently retired as President of Merck Vaccines. At Merck, Dr. Mahmoud led the effort to develop four new vaccines which have been launched in 2005-2006, including: combination of Measles, Mumps, Rubella and Varicella; Rota Virus; Shingles and Human Papillomavirus. His prior academic services at Case Western Reserve University and University Hospitals of Cleveland spanned 25 years concluding as Chairman of Medicine and Physician-in-Chief from 1987 to 1998. Dr. Mahmoud's academic pursuits focused on investigations of host resistance to helminthic infections as well as determinants of infection and disease in human schistosomiasis and other infectious agents. Dr. Mahmoud received his M.D. degree from the University of Cairo in 1963 and Ph.D from the University of London, School of Hygiene and Tropical Medicine in 1971. He was elected to membership of the the Institute of Medicine of the National Academy of Sciences in 1987. He received the Bailey K. Ashford Award of the American Society of Tropical Medicine and Hygiene in 1983, and the Squibb Award of the Infectious Diseases Society of America in 1984. He served on the National Advisory Allergy and Infectious Diseases Council and is a past president of the Central Society for Clinical Research and the International Society for Infectious Diseases. Dr. Mahmoud is currently serving as a member of the National Science Advisory Board for Biosecurity and Committee on Scientific Communications and National Security (CSCANS) of the National Academy of Sciences.